Delivery Order SPE2DR25D1201-SPE2DR26FAJTP
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pens on November 12, 2025, with a ceiling value of $3,322.26 and ultimate completion date of November 13, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued under a competitive procurement process. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens valued at $11,289.63, with an ultimate completion date of August 13, 2025. This non-set-aside competitive award was issued on August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under the company's larger pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 ml pens in 0.5 ml quantities, with a contract ceiling value of $6,863.22. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of October 28, 2025, and performance to be executed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of medical pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 5, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections, with a ceiling value of $6,461.42. This firm fixed-price delivery order is scheduled for completion by November 6, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made on a competitive basis with no set-aside designation, reflecting open competition...
- The Defense Logistics Agency has awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens with a ceiling value of $3,072.24. The contract, which was competitively awarded with no set-aside designation, has a firm fixed price structure and an ultimate completion date of August 8, 2025. AmerisourceBergen will perform this work from its corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $9,870.81 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on September 15, 2025, with an ultimate completion date of September 16, 2025. This non-competitive delivery order represents a firm fixed price transaction under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens in 0.5 mL single-dose units, with a ceiling value of $34,638. This is a firm fixed-price delivery order with an ultimate completion date of November 10, 2025, and represents a non-competitive set-aside award. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections on November 3, 2025, with a completion date of November 4, 2025. This firm fixed price delivery order has a ceiling value of $2,953.12 and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a non-set-aside award issued through open competition, consistent with the company's standard...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections, with a contract ceiling value of $6,841.77. This non-competitive delivery order represents a firm fixed-price transaction with an ultimate completion date of November 7, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued under a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $10,840.04 to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens. This firm fixed-price delivery order, with an ultimate completion date of September 12, 2025, represents a competitively awarded contract with no set-aside designation. The product will be performed and delivered from AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate...
- SPE2DR25D1201Indefinite Delivery Contract
- SPE2DR25D1201-SPE2DR26FAJTPDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on November 12, 2025, with a ceiling value of $10,762.10. This firm fixed-price delivery order is set to be completed by November 13, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. The award represents a single-line pharmaceutical procurement under AmerisourceBergen's broader relationship with the Defense Logistics Agency's medical supply chain operations. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 through December 2026. As a non-set-aside, competitively awarded contract, this procurement demonstrates AmerisourceBergen's continued role as a critical pharmaceutical distributor for federal military and healthcare systems. The contract supports the Defense Health Agency and other government healthcare customers by providing access to brand-name and generic medications, including specialty pharmaceuticals such as Zepbound, across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.8k | 11/12/25 |